 | |
- close
- close
|
Business Wire
Nov 9
Comment
Emisphere Technologies, Inc. (OTC BB: EMIS) today announced financial and operational results for the third quarter and nine months ended September 30, 2009. THIRD QUARTER FINANCIAL RESULTS For the three months ended September 30, 2009, Emisphere
Business Wire
Nov 4
Comment
Emisphere Technologies, Inc. (OTCBB:EMIS) announced today that management will host a conference call to discuss the Company’s financial and operational results for the third quarter ended September 30, 2009 on Monday, November 9, 2009 at 10:00 AM
Business Wire
Nov 2
Comment
Emisphere Technologies, Inc. (OTC BB:EMIS) today announced that interim data from an ongoing study demonstrated its high-dose oral Eligen® B12 (1000mcg) performed as well as or better than B12 injections in individuals with Vitamin B12 deficiency.
Business Wire
Oct 20
Comment
Emisphere Technologies, Inc. (OTC BB:EMIS) today announced study results demonstrating that a single dose of the novel oral parathyroid hormone PTH1-34, which utilizes Emisphere’s proprietary Eligen® Drug Delivery Technology and
Business Wire
Oct 15
Comment
Emisphere Technologies, Inc. (OTCBB: EMIS) announced study results in which twice-daily oral salmon calcitonin using Emisphere’s proprietary Eligen® Drug Delivery Technology significantly suppressed markers of cartilage and bone degradation versus
Business Wire
Oct 8
Comment
Emisphere Technologies, Inc. (OTC BB: EMIS) today announced that the Company is introducing and launching its first commercially available product, oral Eligen® B12 (100 mcg). Oral Eligen® B12 (100 mcg) has been specifically developed to help
Business Wire
Sep 8
Comment
Emisphere Technologies, Inc. (OTC BB: EMIS) today announced the publication of an article in the September issue of Clinical Pharmacology and Therapeutics, that describes previously reported findings of an independent clinical study designed to
Business Wire
Sep 1
Comment
Emisphere Technologies, Inc. (OTC BB: EMIS), a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules and pharmaceutical compounds using its Eligen® Technology, today announced that President and Chief
|
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
|
||
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
EMIS AT A GLANCE
References
| ||||||
|
|
